Key Takeaways
- • The UK Competition and Markets Authority (CMA) has revised ownership disclosure rules for veterinary practices in a way that allows multinational private equity firms to obscure their corporate ownership by using brand names or original practice names instead of disclosing parent company identity.
- • Pet owners pay an average of 16.6% more at large vet groups compared to independent practices, according to the CMA's investigation into the £6.3 billion veterinary market, which found the sector lacks adequate competition and transparency.
- • Over 60% of UK veterinary practices are now owned in whole or in part by six major groups: CVS, Pets at Home, Medivet, IVC, and VetPartners (all private equity-backed), plus Linnaeus (owned by Mars Petcare, a subsidiary of Mars Inc.).
- • The Progressive Veterinary Association has threatened judicial review of the CMA's revised rules, arguing the weakened disclosure requirements enable multinationals to maintain hidden ownership structures that disadvantage consumers and independent practitioners.
- • The CMA's original white paper proposed capping pet medicine prescriptions at £21 and mandating ownership transparency, but subsequent rule modifications have reportedly gutted the transparency provisions while retaining price controls.
Summary
The UK's Competition and Markets Authority faces mounting criticism after revising regulatory requirements designed to increase transparency in veterinary practice ownership. Following a formal investigation into market concentration and anticompetitive practices, the CMA initially proposed rules requiring multinational companies and private equity firms to disclose their true corporate ownership of veterinary clinics. However, subsequent amendments to the regulatory framework now permit these entities to list themselves under brand names or the names of originally independent practices, effectively obscuring beneficial ownership from consumers.
The market dynamics driving this regulatory scrutiny are significant. The CMA's investigation revealed that pet owners pay 16.6% more on average at large veterinary groups than at independent practices. With the UK veterinary market valued at £6.3 billion, this pricing differential represents substantial consumer impact. The inquiry concluded the market structure was "not fit for purpose" and required modernization to restore competitive conditions and consumer awareness. More than 60% of UK veterinary practices are now controlled by six major entities: CVS, Pets at Home, Medivet, IVC, and VetPartners—all backed by private equity investors—alongside Linnaeus, which is owned by Mars Petcare, a subsidiary of the US confectionery conglomerate Mars Inc.
The regulatory reversal has triggered institutional opposition from the veterinary profession itself. The Progressive Veterinary Association, representing practicing veterinarians, has announced plans to pursue judicial review of the CMA's modified rules. The professional body contends that permitting corporations to use alternative naming conventions undermines the transparency objectives established in the CMA's initial white paper published earlier in summer 2026. That original proposal included capped prescription prices for pet medicine at £21 alongside mandatory disclosure of true corporate ownership. The subsequent rule modifications have selectively retained price controls while substantially weakening ownership transparency requirements, creating an enforcement asymmetry that critics argue favors consolidating corporate interests over consumer protection.
The broader implications signal a critical juncture for market regulation in professional services sectors. Private equity consolidation of veterinary practices—mirroring similar patterns in other healthcare and services industries—hinges partly on consumer awareness and price transparency. By permitting ownership opacity while maintaining price caps, the revised rules risk creating a market structure where consumers cannot identify which practices are independently owned, potentially limiting their ability to exercise meaningful choice among service providers. This regulatory outcome may accelerate private equity capital deployment into veterinary consolidation, as the revised transparency requirements significantly reduce reputational or consumer-driven friction that might otherwise constrain valuations or acquisition multiples.
The market dynamics driving this regulatory scrutiny are significant. The CMA's investigation revealed that pet owners pay 16.6% more on average at large veterinary groups than at independent practices. With the UK veterinary market valued at £6.3 billion, this pricing differential represents substantial consumer impact. The inquiry concluded the market structure was "not fit for purpose" and required modernization to restore competitive conditions and consumer awareness. More than 60% of UK veterinary practices are now controlled by six major entities: CVS, Pets at Home, Medivet, IVC, and VetPartners—all backed by private equity investors—alongside Linnaeus, which is owned by Mars Petcare, a subsidiary of the US confectionery conglomerate Mars Inc.
The regulatory reversal has triggered institutional opposition from the veterinary profession itself. The Progressive Veterinary Association, representing practicing veterinarians, has announced plans to pursue judicial review of the CMA's modified rules. The professional body contends that permitting corporations to use alternative naming conventions undermines the transparency objectives established in the CMA's initial white paper published earlier in summer 2026. That original proposal included capped prescription prices for pet medicine at £21 alongside mandatory disclosure of true corporate ownership. The subsequent rule modifications have selectively retained price controls while substantially weakening ownership transparency requirements, creating an enforcement asymmetry that critics argue favors consolidating corporate interests over consumer protection.
The broader implications signal a critical juncture for market regulation in professional services sectors. Private equity consolidation of veterinary practices—mirroring similar patterns in other healthcare and services industries—hinges partly on consumer awareness and price transparency. By permitting ownership opacity while maintaining price caps, the revised rules risk creating a market structure where consumers cannot identify which practices are independently owned, potentially limiting their ability to exercise meaningful choice among service providers. This regulatory outcome may accelerate private equity capital deployment into veterinary consolidation, as the revised transparency requirements significantly reduce reputational or consumer-driven friction that might otherwise constrain valuations or acquisition multiples.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.